Literature DB >> 12075363

Universal immunization of infants with low doses of a low-cost, plasma-derived hepatitis B vaccine in South Africa.

B D Schoub1, U Matai, B Singh, N K Blackburn, J B Levin.   

Abstract

OBJECTIVE: To evaluate the effectiveness of universal vaccination against viral hepatitis B in South Africa among 18-month-old rural children.
METHODS: Children were immunized with a course of low-dose (1.5 microg), plasma-derived hepatitis B vaccine at 6, 10 and 14 weeks of age, and blood samples from the children were tested for three hepatitis B markers: hepatitis B surface antigen (HBsAg), anti-HBs and anti-HBc.
FINDINGS: One year after vaccination, a protective anti-HBs antibody titre of at least 10 IU/l was present in 669/769 (87.0%) of blood serum samples tested. Only 3/756 children (0.4%) were HBsAg positive and a fourth child was anti-HBc positive (HBsAg negative). This is a marked decrease compared to the hepatitis B prevalences reported in previous studies. Among rural migrant mine-workers, for example, HBsAg prevalence was 9.9%, and was 10.1% among children 0-6 years of age in the Eastern Cape Province.
CONCLUSION: The low-dose, plasma-derived hepatitis B vaccine, which is affordable to most developing countries, was very successful in controlling endemic hepatitis B infection, where the virus is predominantly spread by horizontal transmission among infants and young children.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12075363      PMCID: PMC2567767     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Hepatitis B virus infection in post-vaccination South Africa: occult HBV infection and circulating surface gene variants.

Authors:  Edina Amponsah-Dacosta; Ramokone L Lebelo; J Nare Rakgole; Selokela G Selabe; Maemu P Gededzha; Simnikiwe H Mayaphi; Eleanor A Powell; Jason T Blackard; M Jeffrey Mphahlele
Journal:  J Clin Virol       Date:  2014-12-03       Impact factor: 3.168

2.  Maternal hepatitis B and infant infection among pregnant women living with HIV in South Africa.

Authors:  Christopher J Hoffmann; Fildah Mashabela; Silvia Cohn; Jennifer D Hoffmann; Sanjay Lala; Neil A Martinson; Richard E Chaisson
Journal:  J Int AIDS Soc       Date:  2014-05-22       Impact factor: 5.396

Review 3.  The status of hepatitis B control in the African region.

Authors:  Lucy Breakwell; Carol Tevi-Benissan; Lana Childs; Richard Mihigo; Rania Tohme
Journal:  Pan Afr Med J       Date:  2017-06-22

4.  Viral hepatitis B and C in HIV-exposed South African infants.

Authors:  Cynthia Tamandjou Tchuem; Mark Fredric Cotton; Etienne Nel; Richard Tedder; Wolfgang Preiser; Avy Violari; Raziya Bobat; Laura Hovind; Lisa Aaron; Grace Montepiedra; Charles Mitchell; Monique Ingrid Andersson
Journal:  BMC Pediatr       Date:  2020-12-24       Impact factor: 2.125

5.  Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, Malawi.

Authors:  Alexander J Stockdale; James E Meiring; Isaac T Shawa; Deus Thindwa; Niza M Silungwe; Maurice Mbewe; Rabson Kachala; Benno Kreuels; Pratiksha Patel; Priyanka Patel; Marc Y R Henrion; Naor Bar-Zeev; Todd D Swarthout; Robert S Heyderman; Stephen B Gordon; Anna Maria Geretti; Melita A Gordon
Journal:  J Infect Dis       Date:  2022-09-13       Impact factor: 7.759

Review 6.  Hepatitis B Virus (HBV) Subviral Particles as Protective Vaccines and Vaccine Platforms.

Authors:  Joan Kha-Tu Ho; Beena Jeevan-Raj; Hans-Jürgen Netter
Journal:  Viruses       Date:  2020-01-21       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.